Updated Jul 16, 2026 · Last SEC filing 2026-06-18
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) has filed 4 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-06-18. 2 Form 8-K material event filings were reported by ARWR in the last 90 days. 6 Form 144 notices of proposed sale were filed for ARWR stock. InsiderAlpha tracks every ARWR SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.
| SIC classification | Pharmaceutical Preparations (SIC 2834) |
|---|---|
| SEC CIK | 0000879407 |
| Form 4 filings (90d) | 4 |
|---|---|
| Form 8-K filings (90d) | 2 |
| Form 144 notices (90d) | 6 |
| Latest Form 4 filing | 2026-06-18 |
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Cohen Matthew Gregory | Director | A — Grant or award | 11.9K | $0.00 | — | SEC | |
| Lu Hongbo | Director | S — Open-market sale | 3.0K | $76.88 | $228K | SEC | |
| Hamilton James C | Chief Medical Officer | S — Open-market sale | 10.0K | $75.00 | $750K | SEC | |
| Apel Daniel Joseph | Chief Financial Officer | S — Open-market sale | 3.2K | $70.11 | $225K | SEC | |
| Apel Daniel Joseph | Chief Financial Officer | S — Open-market sale | 8.7K | $71.92 | $628K | SEC | |
| Apel Daniel Joseph | Chief Financial Officer | S — Open-market sale | 1.2K | $70.45 | $82K | SEC | |
| Hamilton James C | Chief Medical Officer | S — Open-market sale [10b5-1] | 10.0K | $64.19 | $642K | SEC | |
| Anzalone Christopher Richard | Chief Executive Officer | S — Open-market sale | 14.1K | $62.12 | $876K | SEC | |
| Anzalone Christopher Richard | Chief Executive Officer | S — Open-market sale | 1.3K | $65.77 | $86K | SEC | |
| Anzalone Christopher Richard | Chief Executive Officer | S — Open-market sale | 1.0K | $64.96 | $65K | SEC | |
| Anzalone Christopher Richard | Chief Executive Officer | S — Open-market sale | 166 | $66.77 | $11K | SEC | |
| Anzalone Christopher Richard | Chief Executive Officer | S — Open-market sale | 8.5K | $62.94 | $533K | SEC | |
| Anzalone Christopher Richard | Chief Executive Officer | S — Open-market sale | 11.0K | $61.25 | $671K | SEC | |
| Anzalone Christopher Richard | Chief Executive Officer | S — Open-market sale | 8.4K | $60.51 | $509K | SEC | |
| Anzalone Christopher Richard | Chief Executive Officer | S — Open-market sale | 6.7K | $64.29 | $428K | SEC |
All transactions sourced from SEC EDGAR Form 4 filings for ARROWHEAD PHARMACEUTICALS, INC. (ARWR). Updated in real time as new filings are submitted to the SEC.
| Insider | Form 4 filings | Total transaction value |
|---|---|---|
| Apel Daniel Joseph | 3 | $934K |
| Lu Hongbo | 1 | $228K |
| Hamilton James C | 1 | $750K |
| Cohen Matthew Gregory | 1 | — |
Form 144 must be filed before insiders sell restricted or control stock above SEC thresholds. A cluster of Form 144 notices often precedes a wave of insider distribution.
SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in ARWR insider filings:
| P | Open-market purchase by the insider |
|---|---|
| S | Open-market sale by the insider |
| A | Grant, award, or other acquisition from the issuer |
| M | Exercise or conversion of derivative security (e.g. options) |
| F | Payment of exercise price or tax liability via share withholding |
| G | Bona-fide gift of securities |
| D | Disposition to the issuer (e.g. share buyback participation) |
| J | Other acquisition or disposition |
| X | Exercise of in-the-money or at-the-money derivative security |
| C | Conversion of derivative security |
| V | Transaction voluntarily reported earlier than required |
Open the live ARWR dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.